JP7771076B2 - マスクされたｉｌ－１２サイトカイン及びその切断産物 - Google Patents

マスクされたｉｌ－１２サイトカイン及びその切断産物

Info

Publication number
JP7771076B2
JP7771076B2 JP2022560206A JP2022560206A JP7771076B2 JP 7771076 B2 JP7771076 B2 JP 7771076B2 JP 2022560206 A JP2022560206 A JP 2022560206A JP 2022560206 A JP2022560206 A JP 2022560206A JP 7771076 B2 JP7771076 B2 JP 7771076B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
cytokine
masked
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022560206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520518A (ja
JPWO2021202678A5 (https=
JP2023520518A5 (https=
Inventor
ラファエル ローゼンフェルド，
ウグル エスキオチャク，
ファーウェイ チウ，
パーカー ジョンソン，
カート アレン ジェンキンス，
マガリ ペデルゾリ－リベイル，
ディラージ スィング トマル，
レベカ カイ オドンネル，
Original Assignee
エクシリオ デベロップメント， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクシリオ デベロップメント， インコーポレイテッド filed Critical エクシリオ デベロップメント， インコーポレイテッド
Publication of JP2023520518A publication Critical patent/JP2023520518A/ja
Publication of JPWO2021202678A5 publication Critical patent/JPWO2021202678A5/ja
Publication of JP2023520518A5 publication Critical patent/JP2023520518A5/ja
Priority to JP2025186059A priority Critical patent/JP2026048631A/ja
Application granted granted Critical
Publication of JP7771076B2 publication Critical patent/JP7771076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022560206A 2020-04-01 2021-03-31 マスクされたｉｌ－１２サイトカイン及びその切断産物 Active JP7771076B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025186059A JP2026048631A (ja) 2020-04-01 2025-11-05 マスクされたｉｌ－１２サイトカイン及びその切断産物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063003842P 2020-04-01 2020-04-01
US63/003,842 2020-04-01
US202063118579P 2020-11-25 2020-11-25
US63/118,579 2020-11-25
US202063127893P 2020-12-18 2020-12-18
US63/127,893 2020-12-18
PCT/US2021/025107 WO2021202678A1 (en) 2020-04-01 2021-03-31 Masked il-12 cytokines and their cleavage products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025186059A Division JP2026048631A (ja) 2020-04-01 2025-11-05 マスクされたｉｌ－１２サイトカイン及びその切断産物

Publications (4)

Publication Number Publication Date
JP2023520518A JP2023520518A (ja) 2023-05-17
JPWO2021202678A5 JPWO2021202678A5 (https=) 2024-04-10
JP2023520518A5 JP2023520518A5 (https=) 2024-04-10
JP7771076B2 true JP7771076B2 (ja) 2025-11-17

Family

ID=77929928

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560206A Active JP7771076B2 (ja) 2020-04-01 2021-03-31 マスクされたｉｌ－１２サイトカイン及びその切断産物
JP2025186059A Pending JP2026048631A (ja) 2020-04-01 2025-11-05 マスクされたｉｌ－１２サイトカイン及びその切断産物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025186059A Pending JP2026048631A (ja) 2020-04-01 2025-11-05 マスクされたｉｌ－１２サイトカイン及びその切断産物

Country Status (13)

Country Link
US (1) US20230159603A1 (https=)
EP (1) EP4126249A4 (https=)
JP (2) JP7771076B2 (https=)
KR (1) KR20220161405A (https=)
CN (1) CN115734806A (https=)
AU (1) AU2021248919A1 (https=)
BR (1) BR112022019708A2 (https=)
CA (1) CA3172641A1 (https=)
IL (1) IL296913A (https=)
MX (1) MX2022012312A (https=)
PH (1) PH12022552632A1 (https=)
TW (1) TWI906278B (https=)
WO (1) WO2021202678A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
JP2024511387A (ja) * 2021-03-16 2024-03-13 シートムエックス セラピューティクス，インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
MX2024010488A (es) * 2022-02-28 2024-09-05 Xilio Dev Inc Citocinas dirigidas y metodos de uso de estas.
WO2023220501A1 (en) * 2022-05-12 2023-11-16 Massachusetts Institute Of Technology Activatable therapeutic peptides and uses thereof
US20260035434A1 (en) * 2022-08-01 2026-02-05 Ose Immunotherapeutics Heterodimeric fc-clec-1 fusion molecule and uses thereof
CN117917438A (zh) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
CR20250279A (es) * 2023-01-20 2025-08-25 Boehringer Ingelheim Int Proteínas de fusión fc de il-12
EP4695281A1 (en) * 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216146A1 (en) * 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN121263432A (zh) * 2023-04-12 2026-01-02 上海康抗生物技术有限公司 包含掩蔽型白介素12的多功能分子及使用方法
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025119304A1 (en) * 2023-12-07 2025-06-12 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric proteins against il-12 receptor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108218993A (zh) 2018-01-05 2018-06-29 李华顺 一种以robo1为靶点的双特异性抗体及其制备和应用
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019209965A2 (en) 2018-04-25 2019-10-31 Immune Targeting Inc. Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
JP2022549344A (ja) 2019-09-28 2022-11-24 アスクジーン・ファーマ・インコーポレイテッド サイトカインプロドラッグおよびデュアルプロドラッグ
JP2023518518A (ja) 2020-03-23 2023-05-01 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1489100B1 (en) * 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
AU2013381970A1 (en) * 2013-03-15 2015-10-22 Carnegie Mellon University Linked peptide fluorogenic biosensors
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
JP7358047B2 (ja) * 2016-05-16 2023-10-10 チェックマブ エス．アール．エル． 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー
MX2019004775A (es) * 2016-11-03 2019-08-05 Squibb Bristol Myers Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
CN111527109B (zh) * 2017-12-26 2024-11-01 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
EP3810624A4 (en) * 2018-06-22 2022-07-06 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
CN120463822A (zh) * 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
EP3861016A2 (en) * 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
KR20260017503A (ko) * 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108218993A (zh) 2018-01-05 2018-06-29 李华顺 一种以robo1为靶点的双特异性抗体及其制备和应用
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019209965A2 (en) 2018-04-25 2019-10-31 Immune Targeting Inc. Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
JP2022549344A (ja) 2019-09-28 2022-11-24 アスクジーン・ファーマ・インコーポレイテッド サイトカインプロドラッグおよびデュアルプロドラッグ
JP2023518518A (ja) 2020-03-23 2023-05-01 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法

Also Published As

Publication number Publication date
CA3172641A1 (en) 2021-10-07
JP2023520518A (ja) 2023-05-17
EP4126249A1 (en) 2023-02-08
EP4126249A4 (en) 2024-04-24
CN115734806A (zh) 2023-03-03
TW202204386A (zh) 2022-02-01
BR112022019708A2 (pt) 2022-12-20
KR20220161405A (ko) 2022-12-06
AU2021248919A1 (en) 2022-10-13
US20230159603A1 (en) 2023-05-25
TWI906278B (zh) 2025-12-01
MX2022012312A (es) 2023-02-09
PH12022552632A1 (en) 2023-01-04
WO2021202678A1 (en) 2021-10-07
IL296913A (en) 2022-12-01
JP2026048631A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
JP7771076B2 (ja) マスクされたｉｌ－１２サイトカイン及びその切断産物
JP7735306B2 (ja) マスクされたｉｌ－２サイトカイン及びその切断産物
US11718655B2 (en) Masked interleukin-12 polypeptides
US20230331799A1 (en) Masked il-15 cytokines and their cleavage products
US12280120B2 (en) Tumor-specific cleavable linkers
US20260115302A1 (en) Tumor-specific cleavable linkers
HK40092028A (zh) 掩蔽的il-2细胞因子和其切割产物
HK40090912A (zh) 掩蔽的il-15细胞因子和其切割产物
EA049880B1 (ru) Маскированные цитокиновые полипептиды

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251105

R150 Certificate of patent or registration of utility model

Ref document number: 7771076

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150